Aricept (donepezil) is a brand-name drug that’s prescribed for dementia related to Alzheimer’s disease. Aricept comes as an oral tablet that’s typically taken once per day. Aricept (donepezil) is a ...

Aricept (donepezil) can cause side effects that range from mild to serious. More common side effects include fatigue and nausea. If side effects from Aricept become difficult to tolerate, talk with ...

The prescribed dosage for Aricept (donepezil) may depend on a person’s individual treatment plan. Factors such as the person’s medical history and condition may affect the dosage of Aricept. Aricept ...

The most common side effects of Aricept (donepezil) include insomnia, nausea, and diarrhea. Aricept is not expected to cause any unique side effects in elderly adults. It’s used to treat dementia ...

Eisai got an FDA untitled letter for two Aricept TV ads that the agency said overstate the efficacy of the drug. The ads, “Beach” and “Garden,” feature women recounting seeing the signs of advancing ...

An Alzheimer’s drug did not have an effect on cognitive function in breast cancer survivors. However, one researcher noted reasons why there is still hope. Although Aricept (donepezil), a ...

GENEVA, SWITZERLAND (4 APRIL 2002) - Results from the first head-to-head study comparing ARICEPT® (donepezil HCl tablets) and Reminyl® (galantamine HBr tablets) demonstrated significantly greater ...

New warnings have been added to the prescribing information for the Alzheimer's drug Aricept (donepezil) advising of the risk of two rare but potentially serious conditions: muscle breakdown ...

Salzburg, Austria - Treatment with ARICEPT® (donepezil hydrochloride tablets) significantly improved the cognitive and global (overall) function of patients with vascular dementia (VaD), compared with ...

Eisai and Pfizer announced that the FDA has accepted for review the New Drug Application (NDA) for once-daily 23 mg Aricept (donepezil HCl extended release tablets) for the treatment of moderate to ...

Alzheimer’s disease patients who switched to Pfizer Inc. and Eisai Co.’s long-acting version of Aricept were more likely to maintain or improve brain function than those who continued using an older ...

This follows the very first approval of Aricept for DLB in Japan in September 2014, making the Philippines only the second country in which Aricept has gained this license. An application seeking ...